Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer.
Astrid KramerMarjolein J E GreuterSuzanna J SchraaGeraldine R VinkJillian PhallenVictor E VelculescuGerrit A MeijerDaan van den BroekMiriam KoopmanJeanine M L RoodhartRemond J A FijnemanValesca P RetèlVeerle M H CoupéPublished in: Therapeutic advances in medical oncology (2024)
Adding ctDNA to current high-risk clinicopathological features (pT4 and pMMR) can improve patient selection for ACT and can also potentially be cost-effective. Future studies should investigate the predictive value of post-surgery ctDNA status to accurately evaluate the cost-effectiveness of ctDNA testing for ACT decisions in stage II CC.